HomeGlenmark launches Clobetasol from its niche dermatology pipeline
Date: 17 March 2008
Glenmark launches Clobetasol from its niche
This document is not an offer of securities for sale in the United States or elsewhere. The shares of the Company and its subsidiaries and affiliates are not being registered under the Securities Act and may not be offered or sold in the United States unless registered under the Securities Act or pursuant to an exemption from such registration. There will be no public offering of shares in the United States
dermatology pipeline
Mumbai, March 17, 2008: Glenmark Pharmaceuticals Inc (GPI), the US subsidiary of
Glenmark Pharmaceuticals Limited (Glenmark), one of the world's leading, integrated
specialty pharmaceutical and high-quality generic companies, has commenced
marketing and distribution of five Clobetasol Propionate dermatology products in the US
market.
The Company has acquired the US marketing rights for a line of Clobetasol Propionate
products which include - Cream, E Cream, Ointment, Gel and Topical Solution through
an US based pharmaceutical development company.
Clobetasol Propionate is used to treat diseases such as eczema and psoriasis, where it
is used on the scalp and body. It is also dispensed to counter auto-immune
presentations, such as Alopecia areata (hair loss due to auto-immune diseases) and
Lichen planus (auto immune skin nodules). The total sales for the five above mentioned
Clobetasol Propionate products in the 12 month period ending December 2007 were in
excess of USD 28 million, as per the IMS Health report.
This dermatology portfolio marks Glenmark’s entry into the US semisolid product market.
Based on these recent launches, GPI now has a portfolio of 27 generic products for the
US market. The Company currently has over 35 ANDAs undergoing US FDA approval
process/launch.
About Glenmark Pharmaceuticals Inc., USA [GPI]
Glenmark’s US subsidiary, Glenmark Pharmaceuticals Inc., USA [GPI], was established
in 2003 to enter into the world's largest pharmaceutical market. GPI is responsible for
sales and marketing of generic drug formulations in the USA as well as APIs to
customers in the regulated markets. GPI closed last Fiscal year with sales of USD 50 Mn
from its formulations business.
About Glenmark
Glenmark Pharmaceuticals Ltd. is a research-led, global, fully integrated pharmaceutical
company headquartered in Mumbai, India. The Company is a leader in India in the
discovery of new molecules. Glenmark has 11 lead molecules at various stages of
development in NCE & NBE research. Three of the leads are in Phase II, one in Phase I
Release - Glenmark launches Clobetasol from its niche dermatology pipeline - March, 2008
1 of 2
Glenmark House
HDO – Corporate Building, Wing A
B. D. Sawant Marg, Chakala
Off Western Express Highway
Andheri (E), Mumbai – 99, India
91-22-4018 9999
Email: media@glenmarkpharma.com
and seven other leads are into the pre-clinical and discovery stages in the broad areas
of inflammation, metabolic disorders and oncology.
The Company has generic formulation and API business interests in over 85 countries
across the world including the highly regulated markets of USA and Europe. The
formulation business spans several product segments such as Dermatology, Internal
Medicine, Paediatrics, Gynaecology, ENT, Cardiology, Diabetes and Oncology.
Glenmark’s first Asthma/COPD molecule, Oglemilast [GRC 3886], was licensed out to
Forest Laboratories and Teijin Pharma Limited for the North American and Japanese
markets, respectively, in two landmark deals. Another molecule, GRC 6211 (targeting
pain) which is undergoing Phase II clinical trials in Europe, has recently been out-
licensed to Eli Lilly & company. [www.glenmarkpharma.com]
For further information, please contact:
Ms. Shraddha Bothra
Manager, Corporate Communications
Glenmark Pharmaceuticals Ltd.
Tel : [+91 22] 4018 9919
Fax: [+91 22] 4018 9986
Email: media@glenmarkpharma.com
Download PDF
